Dr. Drilon Discusses CNS Penetration in NSCLC

Alexander Drilon, MD
Published Online: Thursday, Nov 09, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system (CNS) penetration in the treatment of non-small cell lung cancer (NSCLC).

In general, NSCLC tumors like to metastasize to a CNS compartment, says Drilon. Now that tyrosine kinase inhibitors (TKIs) are being tested, it is important to focus on CNS penetration during new drug development.

Drilon says that investigators could take note from studies in ALK-rearranged disease, which has been testing drugs that successfully penetrate the CNS.
 


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system (CNS) penetration in the treatment of non-small cell lung cancer (NSCLC).

In general, NSCLC tumors like to metastasize to a CNS compartment, says Drilon. Now that tyrosine kinase inhibitors (TKIs) are being tested, it is important to focus on CNS penetration during new drug development.

Drilon says that investigators could take note from studies in ALK-rearranged disease, which has been testing drugs that successfully penetrate the CNS.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x